STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 7, 2026, 07:47 AM

Vericel Q1 Revenue +30% to $68.4M; Raises FY26 Guidance to $326-336M

AI Summary

Vericel Corporation reported strong first-quarter 2026 financial results, with total net revenue increasing 30% to $68.4 million. This growth was driven by a 22% rise in MACI net revenue and a 91% surge in Burn Care net revenue. The company also achieved a 72% gross margin and a 195% increase in non-GAAP adjusted EBITDA to $9.6 million, alongside $15.1 million in free cash flow. Based on this performance, Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 million to $336 million.

Key Highlights

  • Total net revenue increased 30% to $68.4 million in Q1 2026.
  • MACI net revenue grew 22% to $56.4 million.
  • Burn Care net revenue surged 91% to $12.0 million.
  • Non-GAAP adjusted EBITDA increased 195% to $9.6 million.
  • Free cash flow was $15.1 million for the quarter.
  • Full-year 2026 revenue guidance raised to $326-$336 million.
  • Gross margin was 72% for the quarter.
  • Net loss was $6.3 million, or $0.12 per diluted share.
VCEL
Biotechnology: Biological Products (No Diagnostic Substances)
Vericel Corp

Price Impact